Pharmaceutical Companies– tag –
-
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highlighting the paradigm shift triggered by Enhertu and the evolving player landscape. In Pa... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, discussed the impact of Enhertu, and looked at how pharma, biotech, and investors are rea... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Multi-billion-dollar acquisitions, mega licensing deals, capacity expansions for ADC manufacturing, and the... -
The Hidden Pitfall of AI Drug Discovery: The Quiet Wall of Reproducibility in Scientific Literature
Introduction: Past Knowledge Is Now the Starting Point of Future Drug Discovery AI-driven drug discovery has become an increasingly central part of modern pharmaceutical R&D. The speed at which novel drug candidates can be identified... -
2026 Global Biotech & Pharma Outlook (Part 2) — Where Technological Progress Is Taking Shape —
Happy New Year. In Part 2, we turn our focus to technological domains where steady and meaningful progress is expected beyond 2026. Rather than highlighting short-lived trends, this article explores areas grounded in scientific necessity... -
2026 Global Biotech & Pharma Outlook (Part 1) — Where Science and Innovation Are Heading —
Happy New Year. At the beginning of a new year, it is often useful to step back from daily headlines and reflect on broader directions. In this article, we explore the global outlook for the biotechnology and pharmaceutical industries as... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #5–#1) — Obesity, ADCs, China Licensing, and M&A Redrew the Map
The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (oralization + access design), ADCs solidifying as a pillar modality, China out-licen... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #10–#6) — The Year “Policy, Safety, and Supply” Decided Winners
In 2025, innovation alone was not enough. Across biotech and pharma, policy, safety, manufacturing reliability, and reimbursement increasingly determined whether breakthroughs could scale in the real world. This first installment (Ranked... -
Aging and Cancer Expert Series – Part 10 Future Directions: Where Might Aging × Cancer Research Go in the Next 10–20 Years?
Introduction: A Map of Aging × Cancer Is Starting to Emerge In this final article of the Expert Series, we step back to ask: Where is aging and cancer research heading over the next 10–20 years? How might these developments change clinic... -
Aging and Cancer Expert Series – Part 9 Modeling Aging and Cancer: From Cells and Organoids to Mice and Human Cohorts
Introduction: Why “Young” Models Struggle to Capture “Old” Cancer Throughout this Expert Series we have discussed: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genotype-specific aging profiles How lymphoma and canc... -
Aging and Cancer Expert Series – Part 8 Geriatric Oncology in Practice: Bringing Aging Biology into Cancer Care
Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: Epigenetic clocks and ImAge as tools to quantify “how old” tissues and cells are Tissue- and genotype-specific pr... -
Aging and Cancer Expert Series – Part 7 Diet, Exercise, Environment, and Geography: External Drivers of Aging × Cancer Risk
Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genot... -
Aging and Cancer Expert Series – Part 6 Does Aging Always Promote Cancer? Insights from KRAS-Driven Lung Cancer
Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: Tools such as epigenetic clocks and ImAge to “visualize” aging Tissue-specific aging profiles and genetic backgrou... -
Aging and Cancer Expert Series – Part 5 Modeling Aging and Cancer: From Cells and Organoids to Whole-Organism and Human Data
Introduction: Why It Is Hard to Model Aging and Cancer Together In earlier parts of this Expert Series, we have discussed: Tools to visualize aging (epigenetic clocks, single-cell profiling, image-based metrics) Tissue-specific aging pro... -
Aging and Cancer Expert Series – Part 4 Reproductive Aging and Women’s Cancers: Linking Ovary, Uterus, and Breast Through Hormones and Molecular Networks
Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: Tools to “visualize” aging (epigenetic clocks, single-cell profiles, image-based metrics) Tissue-specific aging p... -
Aging and Cancer Expert Series – Part 3 Cancer as a Driver of Systemic Aging: Immune, Tissue, and Treatment-Related Pathways
Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: Aging increases the risk of cancer Tissue- and genotype-specific aging patterns shape w... -
Aging and Cancer Expert Series – Part 2 Tissue-Specific Aging Profiles and Genetic Background: Why Cancer Prefers Certain Organs
Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. We saw that people of the same chronologica...
